Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy

被引:86
作者
Kris, MG
Hesketh, PJ
Herrstedt, J
Rittenberg, C
Einhorn, LH
Grunberg, S
Koeller, J
Olver, I
Borjeson, S
Ballatori, E
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
[3] Univ Copenhagen Hosp, DK-2100 Copenhagen, Denmark
[4] Rittenberg Oncol Consulting, Metairie, LA USA
[5] Walther Canc Inst, Indianapolis, IN USA
[6] Vermont Canc Ctr, Shelbourne, VT USA
[7] Univ Texas, Austin, TX 78712 USA
[8] Royal Adelaide Hosp, Ctr Canc, Adelaide, SA 5000, Australia
[9] Linkoping Univ, S-58183 Linkoping, Sweden
[10] Oncol Med, Perugia, Italy
关键词
chemotherapy; aprepitant; dexamethasone; serotonin antagonists; cisplatin;
D O I
10.1007/s00520-004-0699-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This paper uses an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents. We address issues of dose, schedule, and route of administration of five selective 5-HT3 antagonists. We conclude that for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration, even with chemotherapy of high emetic risk. Selective antagonists of the type 3 serotonin receptor (5-HT3) in combination with dexamethasone and aprepitant are the standard of care for the prevention of emesis following chemotherapy of high emetic risk.
引用
收藏
页码:85 / 96
页数:12
相关论文
共 80 条
[1]  
AAPRO E, 2003, P AN M AM SOC CLIN, V22, P726
[2]  
Andrews PLR, 1993, EMESIS ANTICANCER TH, P14
[3]   STRATIFIED, RANDOMIZED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS ONDANSETRON ADMINISTERED AS A MULTIPLE-DOSE REGIMEN VERSUS 2 SINGLE-DOSE REGIMENS IN THE PREVENTION OF CISPLATIN-INDUCED NAUSEA AND VOMITING [J].
BECK, TM ;
HESKETH, PJ ;
MADAJEWICZ, S ;
NAVARI, RM ;
PENDERGRASS, K ;
LESTER, EP ;
KISH, JA ;
MURPHY, WK ;
HAINSWORTH, JD ;
GANDARA, DR ;
BRICKER, LJ ;
KELLER, AM ;
MORTIMER, J ;
GALVIN, DV ;
HOUSE, KW ;
BRYSON, JC .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (12) :1969-1975
[4]   Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects [J].
Blum, RA ;
Majumdar, A ;
McCrea, J ;
Busillo, J ;
Orlowski, LH ;
Panebianco, D ;
Hesney, M ;
Petty, KJ ;
Goldberg, MR ;
Murphy, MG ;
Gottesdiener, KM ;
Hustad, CM ;
Lates, C ;
Kraft, WK ;
Van Buren, S ;
Waldman, SA ;
Greenberg, HE .
CLINICAL THERAPEUTICS, 2003, 25 (05) :1407-1419
[5]   Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone [J].
Campos, D ;
Pereira, JR ;
Reinhardt, RR ;
Carracedo, C ;
Poli, S ;
Vogel, C ;
Martinez-Cedillo, J ;
Erazo, A ;
Wittreich, J ;
Eriksson, LO ;
Carides, AD ;
Gertz, BJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1759-1767
[6]   Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting [J].
Chawla, SP ;
Grunberg, SM ;
Gralla, RJ ;
Hesketh, PJ ;
Rittenberg, C ;
Elmer, ME ;
Schmidt, C ;
Taylor, A ;
Carides, AD ;
Evans, JK ;
Horgan, KJ .
CANCER, 2003, 97 (09) :2290-2300
[7]  
CHEVALLIER B, 1990, EUR J CANCER, V26, pS33
[8]   Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis [J].
Cocquyt, V ;
Van Belie, S ;
Reinhardt, RR ;
Decramer, MLA ;
O'Brien, M ;
Schellens, JHM ;
Borms, M ;
Verbeke, L ;
Van Aelst, F ;
De Smet, M ;
Carides, AD ;
Eldridge, K ;
Gertz, BJ .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (07) :835-842
[9]  
Conte P, 1999, ANTI-CANCER DRUG, V10, P465
[10]   The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy:: a combined analysis of two randomised, placebo-controlled phase III clinical trials [J].
de Wit, R ;
Herrstedt, J ;
Rapoport, B ;
Carides, AD ;
Guoguang-Ma, J ;
Elmer, M ;
Schmidt, C ;
Evans, JK ;
Horgan, KJ .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (03) :403-410